136 results on '"Garajova Ingrid"'
Search Results
2. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
3. Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab
4. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
5. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
6. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
7. A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants
8. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
9. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC
10. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
11. Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study
12. Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population
13. A profile of long-term pancreatic cancer survivors
14. The treatment of rectal cancer with synchronous liver metastases: A matter of strategy
15. Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers
16. Heterotopic auxiliary segment 2–3 liver transplantation with delayed total hepatectomy: New strategies for nonresectable colorectal liver metastases
17. Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications
18. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
19. Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies
20. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary
21. List of Contributors
22. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
23. Perineural Invasion in Pancreatic Ductal Adenocarcinoma: From Molecules towards Drugs of Clinical Relevance
24. Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A
25. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab
26. “Depart from evil, and do good”: Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer
27. A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?
28. Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study
29. Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
30. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary
31. Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development
32. Molecular diagnosis and prognosis of cancers of unknown-primary (CUPs): progress from a microRNA-based droplet digital PCR assay
33. Cancer of unknown primary site-of-origin: an enigma ready to be miR-solved [Abstract]
34. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
35. “Open Sesame?”: Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer
36. Abstract 5432: Cancer of unknown primary site-of-origin: An enigma ready to be miR-solved
37. Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study
38. Chapter 2 - Targeting the Hepatocyte Growth Factor Receptor to Overcome Resistance to Targeted Therapies
39. State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now?
40. P-92 GPS as a prognostic index and a predictor of toxicity in early or locally advanced head and neck cancer patients treated with radiotherapy or definitive chemoradiotherapy
41. Follow-up del cancro del pancreas esocrino
42. Abstract 2596: Spliced messenger RNA of tumor-educated platelets yields a new diagnostic prospective for pancreatic cancer
43. Abstract 3313: Epigenetic biomarkers of prognosis in stage IIA colon cancer
44. D44The overall survival of patients affected by metastatic colorectal cancer before and after 'monoclonal antibodies era': a monocentric retrospective study
45. D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer
46. D43Capecitabine and Regorafenib-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer
47. Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial
48. Clinical features and outcomes of pancreatic cancer patients evaluated for microRNAs as biomarkers of response to treatment during FOLFIRINOX therapy
49. Oxaliplatin in pre-treated patients: maybe not the match point?
50. In Reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.